AR117804A2 - Composiciones farmacéuticas que comprenden una cantidad efectiva de dioxicarbonato de lantano y compuestos de dioxicarbonato de lantano - Google Patents
Composiciones farmacéuticas que comprenden una cantidad efectiva de dioxicarbonato de lantano y compuestos de dioxicarbonato de lantanoInfo
- Publication number
- AR117804A2 AR117804A2 ARP200100076A ARP200100076A AR117804A2 AR 117804 A2 AR117804 A2 AR 117804A2 AR P200100076 A ARP200100076 A AR P200100076A AR P200100076 A ARP200100076 A AR P200100076A AR 117804 A2 AR117804 A2 AR 117804A2
- Authority
- AR
- Argentina
- Prior art keywords
- tablets
- lanthanum
- sodium
- weight
- dioxycarbonate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F17/00—Compounds of rare earth metals
- C01F17/20—Compounds containing only rare earth metals as the metal element
- C01F17/247—Carbonates
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/01—Particle morphology depicted by an image
- C01P2004/03—Particle morphology depicted by an image obtained by SEM
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/61—Micrometer sized, i.e. from 1-100 micrometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/10—Solid density
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/11—Powder tap density
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/12—Surface area
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/14—Pore volume
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/80—Compositional purity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dispersion Chemistry (AREA)
- Geology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Un método para la producción de un compuesto de carbonato de lantano que comprende hacer reaccionar una sal soluble de cloruro de lantano con carbonato de amonio en un solvente a una temperatura de reacción de entre aproximadamente 75 grados C a 90 grados C, a un pH desde 6,0 hasta 7,5 y precipitar el producto de la reacción, donde el producto de la reacción es hidróxido de carbonato de lantano que incluye 0,5% en peso o menos de sodio. El método comprende además calcinar el producto de la reacción a una temperatura de entre 400 y 700 grados C durante por lo menos dos horas para producir dioxicarbonato de lantano que incluye 0,75% en peso o menos de sodio, y comprende uno o más polimorfos seleccionados del grupo que consiste de un polimorfo de la fórmula La₂O₂CO₃ y un polimorfo de la fórmula La₂CO₅. Reivindicación 1: Una composición farmacéutica caracterizada porque comprende una cantidad efectiva de dioxicarbonato de lantano que tiene un volumen de poro de por lo menos 0,015 cm³/g, 0,75% en peso o menos de sodio, y partículas que poseen morfología esférica; y por lo menos un excipiente aceptable desde el punto de vista farmacéutico, en donde dicha composición farmacéutica es una dosificación que se selecciona del grupo que consiste de tabletas que se tragan, comprimidos que se tragan, formas de dosificación comprimidas, cápsulas de gelatina dura que se tragan, cápsulas de gelatina blanda que se tragan, tabletas que se disuelven oralmente, comprimidos que se disuelven oralmente, cápsulas de gelatina dura que se disuelven oralmente, cápsulas de la gelatina blanda que se disuelven oralmente, tabletas masticables, comprimidos masticables, cápsulas masticables, polvos, comprimidos dispersables, películas que se desintegran oralmente, alimentos, golosinas, gomas, jarabes, suspensiones, emulsiones o dispersiones. Reivindicación 4: Un dioxicarbonato de lantano caracterizado porque posee 0,75% en peso o menos de sodio, y poseyendo partículas que poseen morfología esférica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33388710P | 2010-05-12 | 2010-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117804A2 true AR117804A2 (es) | 2021-08-25 |
Family
ID=44279001
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101656A AR081395A1 (es) | 2010-05-12 | 2011-05-13 | Hidroxido de carbonato de lantano oxicarbonato de lantano y metodos para su manufactura y uso |
| ARP200100076A AR117804A2 (es) | 2010-05-12 | 2020-01-10 | Composiciones farmacéuticas que comprenden una cantidad efectiva de dioxicarbonato de lantano y compuestos de dioxicarbonato de lantano |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101656A AR081395A1 (es) | 2010-05-12 | 2011-05-13 | Hidroxido de carbonato de lantano oxicarbonato de lantano y metodos para su manufactura y uso |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US8961917B2 (es) |
| EP (2) | EP3848040A1 (es) |
| JP (4) | JP5993368B2 (es) |
| KR (2) | KR101830456B1 (es) |
| CN (1) | CN103037870B (es) |
| AR (2) | AR081395A1 (es) |
| AU (1) | AU2011252983C1 (es) |
| BR (1) | BR112012028629B8 (es) |
| CA (2) | CA2798081C (es) |
| ES (1) | ES2871021T3 (es) |
| IL (1) | IL222824B (es) |
| MX (1) | MX350075B (es) |
| RU (1) | RU2570007C2 (es) |
| TW (1) | TWI446916B (es) |
| WO (1) | WO2011143475A1 (es) |
| ZA (1) | ZA201209322B (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2798081C (en) | 2010-05-12 | 2024-02-13 | Spectrum Pharmaceuticals, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
| US9575059B2 (en) | 2012-06-05 | 2017-02-21 | 3M Innovative Properties Company | Lanthanum-based concentration agents for microorganisms |
| CN107652289B (zh) | 2012-06-13 | 2020-07-21 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
| JP6449244B2 (ja) | 2013-04-19 | 2019-01-09 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｆｇｆｒ抑制剤としての二環式複素環 |
| CN104129810A (zh) * | 2013-05-02 | 2014-11-05 | 南京大学 | 纯单斜晶相的刺球状碳酸氧镧(La2O2CO3)三维多级结构的制备 |
| CN104592994B (zh) * | 2015-01-14 | 2018-01-02 | 惠州学院 | 一种三角枝状铕掺杂羟基碳酸镧红色荧光粉的制备方法 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
| JP6093829B1 (ja) * | 2015-10-02 | 2017-03-08 | バイエル薬品株式会社 | ランタン化合物を含む医薬組成物 |
| CN105749892B (zh) * | 2016-05-16 | 2018-02-02 | 哈尔滨工业大学 | 一种针对水体除磷的海胆状微球碳酸氧镧吸附剂的制备方法 |
| CN109314212B (zh) * | 2016-06-24 | 2022-02-08 | 日本碍子株式会社 | 包含层状双氢氧化物的功能层及复合材料 |
| CN107188215A (zh) * | 2017-05-24 | 2017-09-22 | 中国北方稀土（集团）高科技股份有限公司 | 碳酸稀土连续沉淀生产过程中自动调节反应终点的方法 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| RU2657755C1 (ru) * | 2017-07-10 | 2018-06-15 | Александр Александрович Кролевец | Способ получения нанокапсул солей лантаноидов в каррагинане |
| WO2019135371A1 (ja) | 2018-01-04 | 2019-07-11 | 旭化成株式会社 | 多孔性成形体 |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| CN119241541A (zh) | 2018-05-04 | 2025-01-03 | 因赛特公司 | Fgfr抑制剂的固体形式和其制备方法 |
| CN111587372B (zh) * | 2018-07-13 | 2023-09-19 | 富士电机株式会社 | 二氧化碳气体传感器 |
| JP7506892B2 (ja) * | 2018-08-21 | 2024-06-27 | 東和薬品株式会社 | 化合物の特定形状の結晶及びその製造方法 |
| JP2020099866A (ja) * | 2018-12-21 | 2020-07-02 | 旭化成株式会社 | 多孔性成形体 |
| RU2693176C1 (ru) * | 2018-12-28 | 2019-07-01 | Общество С Ограниченной Ответственностью "Лаборатория Инновационных Технологий" | Способ получения карбонатов редкоземельных элементов |
| CN109490464A (zh) * | 2019-01-24 | 2019-03-19 | 内蒙古医科大学 | 一种基于离子色谱技术测定稀土药物中镧元素含量的方法 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| IL293001A (en) | 2019-12-04 | 2022-07-01 | Incyte Corp | Derivatives of fgfr repressors |
| CN113029978A (zh) * | 2019-12-25 | 2021-06-25 | 远大生命科学(辽宁)有限公司 | 一种检测含镧试剂的磷结合能力的方法 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN113019305B (zh) * | 2021-03-03 | 2021-10-15 | 重庆三峡学院 | 多孔碱式碳酸镧磷酸盐吸附剂的制备及其应用 |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 |
| CN113311100A (zh) * | 2021-05-27 | 2021-08-27 | 南京诺亚药业有限公司 | 一种碳酸镧制剂中的镧含量的测定方法 |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| CN115487839B (zh) * | 2021-06-17 | 2024-03-26 | 中国石油化工股份有限公司 | 片状催化剂及其制备方法和应用 |
| CN114749182A (zh) * | 2022-03-29 | 2022-07-15 | 中国科学院兰州化学物理研究所 | 一种用于甲烷干重整的镍-氧化镧催化剂及其制备方法 |
| CN116924450B (zh) * | 2022-03-29 | 2025-09-30 | 包头稀土研究院 | 用氯化稀土料液制备碱式碳酸稀土的方法 |
| CN116924449B (zh) * | 2022-03-29 | 2025-12-09 | 包头稀土研究院 | 碱式碳酸镧颗粒及其制备方法 |
| WO2024003337A1 (en) * | 2022-07-01 | 2024-01-04 | Amgmt | Orally administrable pharmaceutical dosage form comprising lanthanum and its use in a method of treatment of hyperoxaluria |
| CN116809015A (zh) * | 2023-04-03 | 2023-09-29 | 中国市政工程中南设计研究总院有限公司 | 一种粘土-碳酸镧复合材料及其制备方法和应用 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3768989A (en) | 1968-08-19 | 1973-10-30 | N Goetzinger | Process for the preparation of a rare earth oxide polishing composition |
| US3692671A (en) | 1970-10-01 | 1972-09-19 | North American Rockwell | Rare earth ion removal from waste water |
| US3922333A (en) | 1973-06-04 | 1975-11-25 | Us Air Force | Process for preparing mullite powder and fabrication of structural bodies therefrom |
| US3922331A (en) | 1973-11-14 | 1975-11-25 | Us Interior | Preparation of microporous rare-earth oxyhalides |
| US4240048A (en) | 1978-12-15 | 1980-12-16 | E. I. Du Pont De Nemours & Co. | Nonlinear optical device |
| ATE5845T1 (de) | 1980-11-14 | 1984-02-15 | Rudolf Schanze | Fuer menschen und tiere geeignetes, spurenelemente enthaltendes konzentrat, ein verfahren zu seiner herstellung und seine verwendung. |
| US4462970A (en) | 1981-08-19 | 1984-07-31 | Hughes Aircraft Company | Process for preparation of water-free oxychloride material |
| US4497785A (en) | 1983-11-18 | 1985-02-05 | Union Oil Company Of California | Production of rare earth compounds |
| JPS60206448A (ja) | 1984-03-29 | 1985-10-18 | Nissan Motor Co Ltd | 排ガス浄化用触媒担体 |
| JPS60226414A (ja) | 1984-04-20 | 1985-11-11 | Hitachi Ltd | ランタン・アルミナ系複合酸化物の製造法 |
| JPS614529A (ja) | 1984-06-15 | 1986-01-10 | Asahi Chem Ind Co Ltd | リン酸イオンの吸着剤 |
| AU601998B2 (en) | 1985-07-11 | 1990-09-27 | Rhone-Poulenc Specialites Chimiques | Oxygenated rare earth derivatives |
| US5782792A (en) | 1986-11-21 | 1998-07-21 | Cypress Bioscience, Inc. | Method for treatment of rheumatoid arthritis |
| US4919902A (en) | 1987-09-30 | 1990-04-24 | Allied-Signal Inc. | Catalyst for treatment of exhaust gases from internal combustion engines |
| FR2623797B2 (fr) | 1987-08-05 | 1990-05-04 | Inst Francais Du Petrole | Procede de conversion du methane en hydrocarbures superieurs |
| US5234957A (en) | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| FR2634398B1 (fr) | 1988-06-29 | 1990-09-07 | Elf Aquitaine | Procede de preparation d'un catalyseur apte a promouvoir la conversion oxydante du methane en hydrocarbures superieurs |
| GB9201857D0 (en) | 1992-01-29 | 1992-03-18 | Smithkline Beecham Plc | Novel compound |
| US5407560A (en) | 1992-03-16 | 1995-04-18 | Japan Energy Corporation | Process for manufacturing petroleum cokes and cracked oil from heavy petroleum oil |
| EP0604919A1 (en) | 1992-12-28 | 1994-07-06 | Ishihara Sangyo Kaisha, Ltd. | Deodorant |
| WO1994019286A1 (en) | 1993-02-24 | 1994-09-01 | Dudley John Mills | Treatment of swimming pool water |
| US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| JPH0810610A (ja) | 1994-07-05 | 1996-01-16 | Ishihara Sangyo Kaisha Ltd | リン吸着剤 |
| GB9506126D0 (en) | 1995-03-25 | 1995-05-10 | Johnson Matthey Plc | Pharmaceutical composition and method |
| US20020183288A1 (en) | 1995-04-03 | 2002-12-05 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US6376479B1 (en) | 1995-04-03 | 2002-04-23 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| GB9611437D0 (en) | 1995-08-03 | 1996-08-07 | Secr Defence | Biomaterial |
| JP2843909B2 (ja) | 1996-05-27 | 1999-01-06 | 科学技術庁無機材質研究所長 | 酸化イットリウム透明焼結体の製造方法 |
| JP3081910B2 (ja) | 1997-08-07 | 2000-08-28 | 工業技術院長 | ヒ素（ｖ）イオンの除去方法 |
| GB9720061D0 (en) | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
| US5843477A (en) | 1997-09-30 | 1998-12-01 | Bayer Corporation | Lubricants for use in tabletting |
| DE69917618T2 (de) | 1998-04-03 | 2005-06-23 | Egalet A/S | Zusammensetzung mit kontrollierter wirkstoff-freisetzung |
| US6197201B1 (en) | 1998-07-29 | 2001-03-06 | The Board Of Regents Of The University & Community College System Of Nevada | Process for removal and stabilization of arsenic and selenium from aqueous streams and slurries |
| US6312604B1 (en) | 1998-10-23 | 2001-11-06 | Zodiac Pool Care, Inc. | Lanthanide halide water treatment compositions and methods |
| WO2001045695A2 (en) | 1999-12-22 | 2001-06-28 | Wisconsin Alumni Research Foundation | Calcium formate for use as a phosphorus binder and a dietary supplement |
| US6338800B1 (en) | 2000-02-22 | 2002-01-15 | Natural Chemistry, Inc. | Methods and compositions using lanthanum for removing phosphates from water |
| US6521647B2 (en) | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
| GB0015745D0 (en) | 2000-06-27 | 2000-08-16 | Shire Holdings Ag | Treatment of bone diseases |
| JP3407039B2 (ja) | 2000-07-10 | 2003-05-19 | 独立行政法人産業技術総合研究所 | ヒ素汚染土壌洗浄剤並びにヒ素汚染土壌安定化剤及びこれらをを用いたヒ素汚染土壌修復方法 |
| FR2811571B1 (fr) | 2000-07-11 | 2002-10-11 | Flamel Tech Sa | Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif |
| US6403523B1 (en) | 2000-09-18 | 2002-06-11 | Union Carbide Chemicals & Plastics Technology Corporation | Catalysts for the oxidative dehydrogenation of hydrocarbons |
| FR2820134A1 (fr) | 2001-01-29 | 2002-08-02 | Rhodia Elect & Catalysis | Oxychlorure de terre rare a surface specifique elevee, ses procedes de preparation et son utilisation comme catalyseur |
| US6849609B2 (en) | 2001-04-10 | 2005-02-01 | James U. Morrison | Method and composition for controlled release acarbose formulations |
| JP4515030B2 (ja) * | 2001-04-23 | 2010-07-28 | アノーメッド インコーポレイティド | 腎臓結石疾患の予防のための希土類化合物の使用 |
| CN1596104A (zh) | 2001-09-28 | 2005-03-16 | 麦克内尔-Ppc股份有限公司 | 改进的释放剂型 |
| US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
| WO2003094933A2 (en) | 2002-05-08 | 2003-11-20 | Shire Holding Ag | Use of lanthanum for the treatment of hypercalcemia and bone metastasis |
| US20040161474A1 (en) * | 2002-05-24 | 2004-08-19 | Moerck Rudi E. | Rare earth metal compounds methods of making, and methods of using the same |
| US20060083791A1 (en) | 2002-05-24 | 2006-04-20 | Moerck Rudi E | Rare earth metal compounds methods of making, and methods of using the same |
| CN100526219C (zh) * | 2002-08-14 | 2009-08-12 | 爱尔达纳米公司 | 稀土金属化合物、其制造方法及其使用方法 |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| AU2003298800B2 (en) | 2002-12-02 | 2007-11-29 | Altairnano, Inc. | Rare earth compositions and structures for removing phosphates from water |
| JP4128906B2 (ja) * | 2003-05-15 | 2008-07-30 | 三井金属鉱業株式会社 | セリウム系研摩材及びセリウム系研摩材の製造方法 |
| US7381428B2 (en) | 2003-08-26 | 2008-06-03 | Shire International Licensing B.V. | Stabilized lanthanum carbonate compositions |
| CZ17621U1 (cs) * | 2003-08-26 | 2007-06-25 | Shire Holdings Ag | Farmaceutický prostredek zahrnující slouceniny lanthanu |
| JP4834953B2 (ja) | 2003-10-31 | 2011-12-14 | 富士ゼロックス株式会社 | 脂肪族ポリケトン類ポリマー及び脂肪族ポリケトン類ポリマー含有組成物の製造方法 |
| US7459502B2 (en) | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| JP2007511528A (ja) | 2003-11-13 | 2007-05-10 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 心肥大および心不全の処置としてのｔｒｐチャネル阻害方法 |
| CN1557982A (zh) | 2004-01-19 | 2004-12-29 | 太原理工大学 | 细化阻燃复合剂及其制备方法 |
| AU2005269362B2 (en) | 2004-07-27 | 2010-08-12 | Shire Pharmaceuticals, Inc. | Method of treating hyperphosphataemia using lanthanum hydroxycarbonate |
| EP1809305A4 (en) | 2004-10-15 | 2009-12-30 | Altairnano Inc | PHOSPHATE BINDER WITH REDUCED TABLE TAKING |
| US20060177415A1 (en) | 2004-11-01 | 2006-08-10 | Burke Steven K | Once a day formulation for phosphate binders |
| EP1698233A1 (en) | 2005-03-01 | 2006-09-06 | Bayer HealthCare AG | Reduction of digestibility of phosphorus in animal nutrition |
| JP2009504423A (ja) | 2005-08-11 | 2009-02-05 | イノヴァライト インコーポレイテッド | 安定にパッシベートされたｉｖ族半導体ナノ粒子、並びにその製造方法及びその組成物 |
| ES2311443T1 (es) | 2005-08-17 | 2009-02-16 | Altairnano, Inc | Hiperfosfatemia en animales domesticos: composiciones y procedimientos de tratamiento. |
| AU2006279343A1 (en) | 2005-08-17 | 2007-02-22 | Altairnano, Inc. | Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods |
| US20070259052A1 (en) * | 2006-05-05 | 2007-11-08 | Shire International Licensing B.V. | Assay for lanthanum hydroxycarbonate |
| CN101077338B (zh) * | 2006-05-24 | 2012-06-20 | 天津大学 | 纳米碳酸镧口腔崩解片及制备方法 |
| CN102696073B (zh) * | 2009-11-06 | 2018-05-18 | 泰拉能源有限责任公司 | 在核裂变反应堆中迁移燃料组件的方法和系统 |
| CA2798081C (en) | 2010-05-12 | 2024-02-13 | Spectrum Pharmaceuticals, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
-
2011
- 2011-05-12 CA CA2798081A patent/CA2798081C/en active Active
- 2011-05-12 US US13/106,637 patent/US8961917B2/en active Active
- 2011-05-12 TW TW100116778A patent/TWI446916B/zh active
- 2011-05-12 KR KR1020127032038A patent/KR101830456B1/ko active Active
- 2011-05-12 BR BR112012028629A patent/BR112012028629B8/pt active IP Right Grant
- 2011-05-12 EP EP21159393.4A patent/EP3848040A1/en active Pending
- 2011-05-12 ES ES11721201T patent/ES2871021T3/es active Active
- 2011-05-12 CA CA3224506A patent/CA3224506A1/en active Pending
- 2011-05-12 WO PCT/US2011/036317 patent/WO2011143475A1/en not_active Ceased
- 2011-05-12 CN CN201180023076.0A patent/CN103037870B/zh active Active
- 2011-05-12 AU AU2011252983A patent/AU2011252983C1/en active Active
- 2011-05-12 KR KR1020177030161A patent/KR101940207B1/ko active Active
- 2011-05-12 EP EP11721201.9A patent/EP2568989B1/en active Active
- 2011-05-12 MX MX2012013065A patent/MX350075B/es active IP Right Grant
- 2011-05-12 JP JP2013510310A patent/JP5993368B2/ja active Active
- 2011-05-12 RU RU2012146818/05A patent/RU2570007C2/ru active
- 2011-05-13 AR ARP110101656A patent/AR081395A1/es active IP Right Grant
-
2012
- 2012-11-01 IL IL222824A patent/IL222824B/en active IP Right Grant
- 2012-12-10 ZA ZA2012/09322A patent/ZA201209322B/en unknown
-
2013
- 2013-12-12 US US14/104,663 patent/US10350240B2/en active Active
-
2016
- 2016-04-07 JP JP2016077533A patent/JP6397845B2/ja active Active
-
2018
- 2018-05-22 JP JP2018097513A patent/JP6938425B2/ja active Active
-
2019
- 2019-06-06 US US16/433,318 patent/US11406663B2/en active Active
-
2020
- 2020-01-10 AR ARP200100076A patent/AR117804A2/es unknown
-
2021
- 2021-09-01 JP JP2021142223A patent/JP7280318B2/ja active Active
-
2022
- 2022-07-11 US US17/861,413 patent/US20220347210A1/en not_active Abandoned
-
2025
- 2025-06-02 US US19/225,647 patent/US20250288608A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117804A2 (es) | Composiciones farmacéuticas que comprenden una cantidad efectiva de dioxicarbonato de lantano y compuestos de dioxicarbonato de lantano | |
| JP2013531598A5 (es) | ||
| US9550878B2 (en) | Method for producing stabilized amorphous calcium carbonate | |
| IN2014MN02106A (es) | ||
| JPWO2016035846A1 (ja) | カテコール基を有するセファロスポリン類を含有する製剤 | |
| HRP20170540T1 (hr) | Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja | |
| WO2012070649A1 (ja) | 溶解性の高いピロロキノリンキノン塩及びその製造方法 | |
| JPWO2014027669A1 (ja) | ピロロキノリンキノンテトラアルカリ塩及びその結晶、これらの製造方法、並びに、組成物 | |
| AR054448A1 (es) | Composiciones farmaceuticas que comprenden acido arsenioso, su sal de sodio y sus derivados destinada al tratamiento de cancer urogenital y de su metastasis | |
| CN103951634A (zh) | 一种依帕司他结晶盐水合物和羟基哌啶共晶物及其制备方法和应用 | |
| HRP20250183T1 (hr) | Hidrokloridna sol 1,5 hidrata heterocikličkog spoja kao derivata | |
| AR060690A1 (es) | Polimeros que contienen magnesio para la hiperfosfatemia | |
| EP4316598A3 (en) | Pharmaceutical composition containing poorly-soluble basic medicine | |
| WO2008093650A1 (ja) | ピペラシリンナトリウムの新規な結晶 | |
| CN103848815B (zh) | 含脲基片段的4-取代-6-苯基嘧啶衍生物及其制备方法和用途 | |
| US12233081B2 (en) | Hygromycin a compounds and methods of treating spirochete diseases | |
| MX2013012773A (es) | Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas. | |
| ES2966833T3 (es) | Quelato de metionina-metal y método de producción del mismo | |
| CA2595815A1 (en) | Salt form of a dopamine agonist | |
| ES2664023T3 (es) | Nuevo compuesto, su procedimiento de producción y uso de dicho compuesto | |
| CN111630045A (zh) | 喹啉衍生物的结晶 | |
| CN101974021B (zh) | 一种头孢呋辛酸的合成方法 | |
| EP2801565B1 (en) | Compounds for use as anti-ulcer agent and/or anti-Helicobacter pylori agent and pharmaceutical compositions thereof | |
| CN108264465B (zh) | 盐酸达泊西汀一水合物及其制备方法和用途 | |
| CN103288773A (zh) | 一种非布司他金属盐及其制备方法 |